Elinzanetant
Hot Flashes
BayerSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Hot Flashes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Mayo Clinic | Phase 3 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Northwestern University | Phase 4 | BB |
Seroquel® McMaster University | Phase 4 | BB |
TAMOXIFEN Astellas Pharma Global Development, Inc. | Phase 3 | BB |
DESVENLAFAXINE Seoul National University Hospital | Phase 4 | BB |
View all 31 →
Same molecule, other indications
Elinzanetant is also rated in:
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerDormant
B
Indicative ·
60 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →